Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer

References

• Bastus NC, Boyd LK, Mao X, Stankiewicz E, Kudahetti SC, Oliver RT, Berney DM, Lu YJ. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 2010; 70(23):9544-8; PMID:20947519; http://dx.doi.org/10.1158/0008-5472.CAN-10-1638
   PubMed Web of Science ®Google Scholar
• Liu X, Choi RY, Jawad SM, Arnold JT. Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells. Prostate 2011; 71(7):766-77; PMID:21031436; http://dx.doi.org/10.1002/pros.21293
   PubMed Web of Science ®Google Scholar
• Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 2014; 50(9):1617-27; PMID:24703899; http://dx.doi.org/10.1016/j.ejca.2014.03.010
   PubMed Web of Science ®Google Scholar
• Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009; 15(10):3251-5; PMID:19447877; http://dx.doi.org/10.1158/1078-0432.CCR-08-1171
   PubMed Web of Science ®Google Scholar
• Ford OH 3rd, Gregory CW, Kim D, Smitherman AB, Mohler JL. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 2003; 170(5):1817-21; PMID:14532783; http://dx.doi.org/10.1097/01.ju.0000091873.09677.f4
   PubMed Web of Science ®Google Scholar
• Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63(1):149-53; PMID:12517791
   PubMed Web of Science ®Google Scholar
• Aaronson DS, Muller M, Neves SR, Chung WC, Jayaram G, Iyengar R, Ram PT. An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells. Mol Cell Endocrinol 2007; 270(1–2):50-6; PMID:17374439; http://dx.doi.org/10.1016/j.mce.2007.02.006
   PubMed Web of Science ®Google Scholar
• Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004; 64(23):8620-9; PMID:15574769; http://dx.doi.org/10.1158/0008-5472.CAN-04-2446
   PubMed Web of Science ®Google Scholar
• Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10(10):981-91; PMID:19796750; http://dx.doi.org/10.1016/S1470-2045(09)70229-3
   PubMed Web of Science ®Google Scholar
• Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9(8):643-60; PMID:20671765; http://dx.doi.org/10.1038/nrd3184
   PubMed Web of Science ®Google Scholar
• Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters JM. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007; 17(4):304-15; PMID:17291761; http://dx.doi.org/10.1016/j.cub.2006.12.046
   PubMed Web of Science ®Google Scholar
• Triscott J, Lee C, Foster C, Manoranjan B, Pambid MR, Berns R, Fotovati A, Venugopal C, O'Halloran K, Narendran A, et al. Personalizing the treatment of pediatric medulloblastoma: polo-like kinase 1 as a molecular target in high-risk children. Cancer Res 2013; 73(22):6734-44; PMID:24019381; http://dx.doi.org/10.1158/0008-5472.CAN-12-4331
   PubMed Web of Science ®Google Scholar
• Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther 2012; 11(4):1006-16; PMID:22319201; http://dx.doi.org/10.1158/1535-7163.MCT-11-0765
   PubMed Web of Science ®Google Scholar
• Markant SL, Esparza LA, Sun J, Barton KL, McCoig LM, Grant GA, Crawford JR, Levy ML, Northcott PA, Shih D, et al. Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases. Cancer Res 2013; 73(20):6310-22; PMID:24067506; http://dx.doi.org/10.1158/0008-5472.CAN-12-4258
   PubMed Web of Science ®Google Scholar
• Schoffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, et al. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer 2010; 46(12):2206-15; PMID:20471824; http://dx.doi.org/10.1016/j.ejca.2010.03.039
   PubMed Web of Science ®Google Scholar
• Liu XS, Song B, Elzey BD, Ratliff TL, Konieczny SF, Cheng L, Ahmad N, Liu X. Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J Biol Chem 2011; 286(41):35795-800; PMID:21890624; http://dx.doi.org/10.1074/jbc.C111.269050
   PubMed Web of Science ®Google Scholar
• Deeraksa A, Pan J, Sha Y, Liu XD, Eissa NT, Lin SH, Yu-Lee LY. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis. Oncogene 2013; 32(24):2973-83; PMID:22890325; http://dx.doi.org/10.1038/onc.2012.309
   PubMed Web of Science ®Google Scholar
• Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69(1):16-22; PMID:19117982; http://dx.doi.org/10.1158/0008-5472.CAN-08-2764
   PubMed Web of Science ®Google Scholar
• Ozbay T, Rowan A, Leon A, Patel P, Sewer MB. Cyclic adenosine 5'-monophosphate-dependent sphingosine-1-phosphate biosynthesis induces human CYP17 gene transcription by activating cleavage of sterol regulatory element binding protein 1. Endocrinology 2006; 147(3):1427-37; PMID:16306078; http://dx.doi.org/10.1210/en.2005-1091
   PubMed Web of Science ®Google Scholar
• Froehner M, Wirth MP. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371(18):1755; PMID:25354111; http://dx.doi.org/10.1056/NEJMc1410239
   PubMed Web of Science ®Google Scholar
• Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci 2011; 68(24):3971-81; PMID:21748469; http://dx.doi.org/10.1007/s00018-011-0766-7
   PubMed Web of Science ®Google Scholar
• Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15(15):4799-805; PMID:19638457; http://dx.doi.org/10.1158/1078-0432.CCR-08-0125
   PubMed Web of Science ®Google Scholar
• Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19(5):575-86; PMID:21575859; http://dx.doi.org/10.1016/j.ccr.2011.04.008
   PubMed Web of Science ®Google Scholar
• Zhang Z, Hou X, Shao C, Li J, Cheng JX, Kuang S, Ahmad N, Ratliff T, Liu X. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. Cancer Res 2014; 74(22):6635-47; PMID:25252916; http://dx.doi.org/10.1158/0008-5472.CAN-14-1916
   PubMed Web of Science ®Google Scholar
• Hou X, Li Z, Huang W, Li J, Staiger C, Kuang S, Ratliff T, Liu X. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate 2013; 73(12):1352-63; PMID:23661607; http://dx.doi.org/10.1002/pros.22683
   PubMed Web of Science ®Google Scholar
• Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011; 71(20):6503-13; PMID:21868758; http://dx.doi.org/10.1158/0008-5472.CAN-11-0532
   PubMed Web of Science ®Google Scholar
• Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138(2):245-56; PMID:19632176; http://dx.doi.org/10.1016/j.cell.2009.04.056
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011; 17(18):5913-25; PMID:21807635; http://dx.doi.org/10.1158/1078-0432.CCR-11-0728
   PubMed Web of Science ®Google Scholar
• Yin L, Hu Q. CYP17 inhibitors–abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nat Rev Urol 2014; 11(1):32-42; PMID:24276076; http://dx.doi.org/10.1038/nrurol.2013.274
   PubMed Web of Science ®Google Scholar